{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:47:08Z","timestamp":1793072828707,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/01098"],"award-info":[{"award-number":["PI18\/01098"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Genom. Med."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Most consensus recommendations for the genetic diagnosis of neurodevelopmental disorders (NDDs) do not include the use of next generation sequencing (NGS) and are still based on chromosomal microarrays, such as comparative genomic hybridization array (aCGH). This study compares the diagnostic yield obtained by aCGH and clinical exome sequencing in NDD globally and its spectrum of disorders. To that end, 1412 patients clinically diagnosed with NDDs and studied with aCGH were classified into phenotype categories: global developmental delay\/intellectual disability (GDD\/ID); autism spectrum disorder (ASD); and other NDDs. These categories were further subclassified based on the most frequent accompanying signs and symptoms into isolated forms, forms with epilepsy; forms with micro\/macrocephaly and syndromic forms. Two hundred and forty-five patients of the 1412 were subjected to clinical exome sequencing. Diagnostic yield of aCGH and clinical exome sequencing, expressed as the number of solved cases, was compared for each phenotype category and subcategory. Clinical exome sequencing was superior than aCGH for all cases except for isolated ASD, with no additional cases solved by NGS. Globally, clinical exome sequencing solved 20% of cases (versus 5.7% by aCGH) and the diagnostic yield was highest for all forms of GDD\/ID and lowest for Other NDDs (7.1% versus 1.4% by aCGH) and ASD (6.1% versus 3% by aCGH). In the majority of cases, diagnostic yield was higher in the phenotype subcategories than in the mother category. These results suggest that NGS could be used as a first-tier test in the diagnostic algorithm of all NDDs followed by aCGH when necessary.<\/jats:p>","DOI":"10.1038\/s41525-021-00188-7","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T11:06:58Z","timestamp":1616670418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Comparison of the diagnostic yield of aCGH and genome-wide sequencing across different neurodevelopmental disorders"],"prefix":"10.1038","volume":"6","author":[{"given":"Francisco","family":"Martinez-Granero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Blanco-Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Sanchez-Jimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Avila-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Arteche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Bustamante-Aragones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2339-6872","authenticated-orcid":false,"given":"Cristina","family":"Rodilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Rodr\u00edguez-Pinilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Riveiro-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3684-9076","authenticated-orcid":false,"given":"Saoud","family":"Tahsin-Swafiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Trujillo-Tiebas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9242-7065","authenticated-orcid":false,"given":"Carmen","family":"Ayuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rodr\u00edguez de Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Lorda-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-2954","authenticated-orcid":false,"given":"Berta","family":"Almoguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"188_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S2215-0366(16)30376-5","volume":"4","author":"A Thapar","year":"2017","unstructured":"Thapar, A., Cooper, M. & Rutter, M. Neurodevelopmental disorders. Lancet Psychiatry 4, 339\u2013346 (2017).","journal-title":"Lancet Psychiatry"},{"key":"188_CR2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"AP Association","year":"2013","unstructured":"Association, A. P. Diagnostic and Statistical Manual of Mental Disorders. 5th edition edn (American Psychiatric Association, 2013).","edition":"5th edition edn"},{"key":"188_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1146\/annurev-genom-082509-141640","volume":"11","author":"HH Ropers","year":"2010","unstructured":"Ropers, H. H. Genetics of early onset cognitive impairment. Annu. Rev. Genomics Hum. Genet. 11, 161\u2013187 (2010).","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"188_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nrg.2017.4","volume":"18","author":"JAS Vorstman","year":"2017","unstructured":"Vorstman, J. A. S. et al. Autism genetics: opportunities and challenges for clinical translation. Nat. Rev. Genet. 18, 362\u2013376 (2017).","journal-title":"Nat. Rev. Genet."},{"key":"188_CR5","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/s41436-019-0554-6","volume":"21","author":"S Srivastava","year":"2019","unstructured":"Srivastava, S. et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet. Med. 21, 2413\u20132421 (2019).","journal-title":"Genet. Med."},{"key":"188_CR6","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/GIM.0b013e31821dd54a","volume":"13","author":"ME Coulter","year":"2011","unstructured":"Coulter, M. E. et al. Chromosomal microarray testing influences medical management. Genet. Med. 13, 770\u2013776 (2011).","journal-title":"Genet. Med."},{"key":"188_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41525-018-0053-8","volume":"3","author":"MM Clark","year":"2018","unstructured":"Clark, M. M. et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. NPJ Genom. Med. 3, 16 (2018).","journal-title":"NPJ Genom. Med."},{"key":"188_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/gim.2013.32","volume":"15","author":"GB Schaefer","year":"2013","unstructured":"Schaefer, G. B., Mendelsohn, N. J., Professional, P. & Guidelines, C. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. Genet. Med. 15, 399\u2013407 (2013).","journal-title":"Genet. Med."},{"key":"188_CR9","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/GIM.0b013e3181f8baad","volume":"12","author":"M Manning","year":"2010","unstructured":"Manning, M., Hudgins, L., Professional, P. & Guidelines, C. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet. Med. 12, 742\u2013745 (2010).","journal-title":"Genet. Med."},{"key":"188_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.ajhg.2010.04.006","volume":"86","author":"DT Miller","year":"2010","unstructured":"Miller, D. T. et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am. J. Hum. Genet. 86, 749\u2013764 (2010).","journal-title":"Am. J. Hum. Genet."},{"key":"188_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3343\/alm.2018.38.5.473","volume":"38","author":"JS Lee","year":"2018","unstructured":"Lee, J. S. et al. Chromosomal microarray with clinical diagnostic utility in children with developmental delay or intellectual disability. Ann. Lab. Med. 38, 473\u2013480 (2018).","journal-title":"Ann. Lab. Med."},{"key":"188_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3343\/alm.2019.39.3.299","volume":"39","author":"W Jang","year":"2019","unstructured":"Jang, W. et al. Chromosomal microarray analysis as a first-tier clinical diagnostic test in patients with developmental delay\/intellectual disability, autism spectrum disorders, and multiple congenital anomalies: a prospective multicenter study in Korea. Ann. Lab. Med. 39, 299\u2013310 (2019).","journal-title":"Ann. Lab. Med."},{"key":"188_CR13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/cge.12732","volume":"89","author":"J Thevenon","year":"2016","unstructured":"Thevenon, J. et al. Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole-exome sequencing as a first-line diagnostic test. Clin. Genet. 89, 700\u2013707 (2016).","journal-title":"Clin. Genet."},{"key":"188_CR14","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/s41431-018-0203-6","volume":"26","author":"T Vrijenhoek","year":"2018","unstructured":"Vrijenhoek, T. et al. Whole-exome sequencing in intellectual disability; cost before and after a diagnosis. Eur. J. Hum. Genet. 26, 1566\u20131571 (2018).","journal-title":"Eur. J. Hum. Genet."},{"key":"188_CR15","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nn.4589","volume":"20","author":"MR Geisheker","year":"2017","unstructured":"Geisheker, M. R. et al. Hotspots of missense mutation identify neurodevelopmental disorder genes and functional domains. Nat. Neurosci. 20, 1043\u20131051 (2017).","journal-title":"Nat. Neurosci."},{"key":"188_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0675-1","volume":"11","author":"A Lindstrand","year":"2019","unstructured":"Lindstrand, A. et al. From cytogenetics to cytogenomics: whole-genome sequencing as a first-line test comprehensively captures the diverse spectrum of disease-causing genetic variation underlying intellectual disability. Genome. Med. 11, 68 (2019).","journal-title":"Genome. Med."},{"key":"188_CR17","first-page":"649","volume":"23","author":"J Han","year":"2017","unstructured":"Han, J. et al. Diagnostic application of clinical exome sequencing in Leber congenital amaurosis. Mol. Vis. 23, 649\u2013659 (2017).","journal-title":"Mol. Vis."},{"key":"188_CR18","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.3389\/fimmu.2019.02325","volume":"10","author":"F Rudilla","year":"2019","unstructured":"Rudilla, F. et al. Expanding the clinical and genetic spectra of primary immunodeficiency-related disorders with clinical exome sequencing: expected and unexpected findings. Front. Immunol. 10, 2325 (2019).","journal-title":"Front. Immunol."},{"key":"188_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-019-2203-8","volume":"13","author":"M Sahli","year":"2019","unstructured":"Sahli, M. et al. Clinical exome sequencing identifies two novel mutations of the SCN1A and SCN2A genes in Moroccan patients with epilepsy: a case series. J. Med. Case Rep. 13, 266 (2019).","journal-title":"J. Med. Case Rep."},{"key":"188_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nature13908","volume":"515","author":"I Iossifov","year":"2014","unstructured":"Iossifov, I. et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature 515, 216\u2013221 (2014).","journal-title":"Nature"},{"key":"188_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrg3585","volume":"15","author":"M Ronemus","year":"2014","unstructured":"Ronemus, M., Iossifov, I., Levy, D. & Wigler, M. The role of de novo mutations in the genetics of autism spectrum disorders. Nat. Rev. Genet. 15, 133\u2013141 (2014).","journal-title":"Nat. Rev. Genet."},{"key":"188_CR22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.ajhg.2016.06.036","volume":"99","author":"VM Leppa","year":"2016","unstructured":"Leppa, V. M. et al. Rare inherited and de novo CNVs reveal complex contributions to ASD risk in multiplex families. Am. J. Hum. Genet. 99, 540\u2013554 (2016).","journal-title":"Am. J. Hum. Genet."},{"key":"188_CR23","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.cell.2019.07.015","volume":"178","author":"EK Ruzzo","year":"2019","unstructured":"Ruzzo, E. K. et al. Inherited and de novo genetic risk for autism impacts shared networks. Cell 178, 850\u2013866 e826 (2019).","journal-title":"Cell"},{"key":"188_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.cell.2019.12.036","volume":"180","author":"FK Satterstrom","year":"2020","unstructured":"Satterstrom, F. K. et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell 180, 568\u2013584 e523 (2020).","journal-title":"Cell"},{"key":"188_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejpn.2013.04.010","volume":"17","author":"A Battaglia","year":"2013","unstructured":"Battaglia, A. et al. Confirmation of chromosomal microarray as a first-tier clinical diagnostic test for individuals with developmental delay, intellectual disability, autism spectrum disorders and dysmorphic features. Eur. J. Paediatr. Neurol. 17, 589\u2013599 (2013).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"188_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.anpedi.2017.07.011","volume":"89","author":"N Castells-Sarret","year":"2018","unstructured":"Castells-Sarret, N. et al. [Comparative genomic hybridisation as a first option in genetic diagnosis: 1,000 cases and a cost-benefit analysis]. An. Pediatr. 89, 3\u201311, https:\/\/doi.org\/10.1016\/j.anpedi.2017.07.011 (2018).","journal-title":"An. Pediatr."},{"key":"188_CR27","volume":"8","author":"I Catusi","year":"2020","unstructured":"Catusi, I. et al. Testing single\/combined clinical categories on 5110 Italian patients with developmental phenotypes to improve array-based detection rate. Mol. Genet Genom. Med. 8, e1056 (2020).","journal-title":"Mol. Genet Genom. Med."},{"key":"188_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/cdev.12050","volume":"84","author":"AL Beaudet","year":"2013","unstructured":"Beaudet, A. L. The utility of chromosomal microarray analysis in developmental and behavioral pediatrics. Child Dev. 84, 121\u2013132 (2013).","journal-title":"Child Dev."},{"key":"188_CR29","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ejpn.2014.04.010","volume":"18","author":"M Rosello","year":"2014","unstructured":"Rosello, M. et al. Phenotype profiling of patients with intellectual disability and copy number variations. Eur. J. Paediatr. Neurol. 18, 558\u2013566 (2014).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"188_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1824-7288-40-39","volume":"40","author":"E Caramaschi","year":"2014","unstructured":"Caramaschi, E. et al. Predictive diagnostic value for the clinical features accompanying intellectual disability in children with pathogenic copy number variations: a multivariate analysis. Ital. J. Pediatr. 40, 39 (2014).","journal-title":"Ital. J. Pediatr."},{"key":"188_CR31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.nrl.2016.03.006","volume":"32","author":"V Caballero Perez","year":"2017","unstructured":"Caballero Perez, V. et al. Phenotype in patients with intellectual disability and pathological results in array CGH. Neurologia 32, 568\u2013578 (2017).","journal-title":"Neurologia"},{"key":"188_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/gim.2016.88","volume":"19","author":"AM Wenger","year":"2017","unstructured":"Wenger, A. M., Guturu, H., Bernstein, J. A. & Bejerano, G. Systematic reanalysis of clinical exome data yields additional diagnoses: implications for providers. Genet. Med. 19, 209\u2013214 (2017).","journal-title":"Genet. Med."},{"key":"188_CR33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/cge.13438","volume":"94","author":"M Al-Nabhani","year":"2018","unstructured":"Al-Nabhani, M. et al. Reanalysis of exome sequencing data of intellectual disability samples: yields and benefits. Clin. Genet. 94, 495\u2013501 (2018).","journal-title":"Clin. Genet."},{"key":"188_CR34","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/gim.2018.39","volume":"20","author":"LJ Ewans","year":"2018","unstructured":"Ewans, L. J. et al. Whole-exome sequencing reanalysis at 12 months boosts diagnosis and is cost-effective when applied early in Mendelian disorders. Genet Med. 20, 1564\u20131574 (2018).","journal-title":"Genet Med."},{"key":"188_CR35","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.gene.2019.03.037","volume":"700","author":"J Li","year":"2019","unstructured":"Li, J. et al. Reanalysis of whole exome sequencing data in patients with epilepsy and intellectual disability\/mental retardation. Gene 700, 168\u2013175 (2019).","journal-title":"Gene"},{"key":"188_CR36","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.tig.2019.08.006","volume":"35","author":"Z Liu","year":"2019","unstructured":"Liu, Z., Zhu, L., Roberts, R. & Tong, W. Toward clinical implementation of next-generation sequencing-based genetic testing in rare diseases: where are we? Trends Genet. 35, 852\u2013867 (2019).","journal-title":"Trends Genet."},{"key":"188_CR37","doi-asserted-by":"publisher","unstructured":"Borch, L. A., Parboosingh, J., Thomas, M. A. & Veale, P. Re-evaluating the first-tier status of fragile X testing in neurodevelopmental disorders. Genet. Med. https:\/\/doi.org\/10.1038\/s41436-020-0773-x (2020).","DOI":"10.1038\/s41436-020-0773-x"},{"key":"188_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s004390050909","volume":"104","author":"T Kubota","year":"1999","unstructured":"Kubota, T. et al. A new assay for the analysis of X-chromosome inactivation based on methylation-specific PCR. Hum. Genet. 104, 49\u201355 (1999).","journal-title":"Hum. Genet."},{"key":"188_CR39","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1159\/000334066","volume":"135","author":"AC Gijsbers","year":"2011","unstructured":"Gijsbers, A. C., Schoumans, J. & Ruivenkamp, C. A. Interpretation of array comparative genome hybridization data: a major challenge. Cytogenet Genome Res. 135, 222\u2013227 (2011).","journal-title":"Cytogenet Genome Res."},{"key":"188_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ejhg.2011.174","volume":"20","author":"NM Hanemaaijer","year":"2012","unstructured":"Hanemaaijer, N. M. et al. Practical guidelines for interpreting copy number gains detected by high-resolution array in routine diagnostics. Eur. J. Hum. Genet. 20, 161\u2013165 (2012).","journal-title":"Eur. J. Hum. Genet."},{"key":"188_CR41","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"188_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ejhg.2015.226","volume":"24","author":"G Matthijs","year":"2016","unstructured":"Matthijs, G. et al. Guidelines for diagnostic next-generation sequencing. Eur. J. Hum. Genet. 24, 2\u20135 (2016).","journal-title":"Eur. J. Hum. Genet."},{"key":"188_CR43","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/jmedgenet-2018-105879","volume":"56","author":"AE Jonch","year":"2019","unstructured":"Jonch, A. E. et al. Estimating the effect size of the 15Q11.2 BP1-BP2 deletion and its contribution to neurodevelopmental symptoms: recommendations for practice. J. Med. Genet. 56, 701\u2013710 (2019).","journal-title":"J. Med. Genet."}],"container-title":["npj Genomic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41525-021-00188-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41525-021-00188-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41525-021-00188-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T20:48:23Z","timestamp":1670014103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41525-021-00188-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["188"],"URL":"https:\/\/doi.org\/10.1038\/s41525-021-00188-7","relation":{},"ISSN":["2056-7944"],"issn-type":[{"value":"2056-7944","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"21 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}